Suppr超能文献

相似文献

1
Axonal Charcot-Marie-Tooth Disease: from Common Pathogenic Mechanisms to Emerging Treatment Opportunities.
Neurotherapeutics. 2021 Oct;18(4):2269-2285. doi: 10.1007/s13311-021-01099-2. Epub 2021 Oct 4.
2
Charcot-Marie-Tooth disease: emerging mechanisms and therapies.
Int J Biochem Cell Biol. 2012 Aug;44(8):1299-304. doi: 10.1016/j.biocel.2012.04.020. Epub 2012 Apr 30.
3
Genetic epidemiology of Charcot-Marie-Tooth disease.
Acta Neurol Scand Suppl. 2012(193):iv-22. doi: 10.1111/ane.12013.
4
Overlapping spectrums: The clinicogenetic commonalities between Charcot-Marie-Tooth and other neurodegenerative diseases.
Brain Res. 2020 Jan 15;1727:146532. doi: 10.1016/j.brainres.2019.146532. Epub 2019 Oct 31.
5
HDAC6 is a therapeutic target in mutant GARS-induced Charcot-Marie-Tooth disease.
Brain. 2018 Mar 1;141(3):673-687. doi: 10.1093/brain/awx375.
6
Axonal Charcot-Marie-Tooth disease.
Curr Opin Neurol. 2011 Oct;24(5):475-83. doi: 10.1097/WCO.0b013e32834aa331.
7
Emerging Therapies for Charcot-Marie-Tooth Inherited Neuropathies.
Int J Mol Sci. 2021 Jun 3;22(11):6048. doi: 10.3390/ijms22116048.
9
ALS5/SPG11/KIAA1840 mutations cause autosomal recessive axonal Charcot-Marie-Tooth disease.
Brain. 2016 Jan;139(Pt 1):73-85. doi: 10.1093/brain/awv320. Epub 2015 Nov 10.
10
Mutations in the MORC2 gene cause axonal Charcot-Marie-Tooth disease.
Brain. 2016 Jan;139(Pt 1):62-72. doi: 10.1093/brain/awv311. Epub 2015 Oct 24.

引用本文的文献

1
Modulating mitochondrial dynamics in CMT2A: a multifaceted platform for drug discovery and evaluation.
Biophys Rep. 2025 Jun 30;11(3):143-155. doi: 10.52601/bpr.2024.240037.
2
One gene, many phenotypes: the role of KIF5A in neurodegenerative and neurodevelopmental diseases.
Cell Commun Signal. 2025 Jun 16;23(1):287. doi: 10.1186/s12964-025-02277-x.
3
Mitochondria-Associated Membranes: A Key Point of Neurodegenerative Diseases.
CNS Neurosci Ther. 2025 May;31(5):e70378. doi: 10.1111/cns.70378.
4
SARM1: The Checkpoint of Axonal Degeneration in the Nervous System Disorders.
Mol Neurobiol. 2025 Mar 17. doi: 10.1007/s12035-025-04835-3.
5
Charcot-Marie-Tooth disease: A case report initially manifested by bilateral vocal cord paralysis.
Respir Med Case Rep. 2025 Jan 8;53:102154. doi: 10.1016/j.rmcr.2024.102154. eCollection 2025.
7
A novel missense mutation causes autosomal dominant Charcot-Marie-Tooth disease type 4B3.
Front Neurol. 2024 Nov 22;15:1495711. doi: 10.3389/fneur.2024.1495711. eCollection 2024.
8
Clinical Outcome Assessments and Biomarkers in Charcot-Marie-Tooth Disease.
Neurology. 2024 Dec 24;103(12):e210120. doi: 10.1212/WNL.0000000000210120. Epub 2024 Nov 25.
10
Current Treatment Methods for Charcot-Marie-Tooth Diseases.
Biomolecules. 2024 Sep 9;14(9):1138. doi: 10.3390/biom14091138.

本文引用的文献

1
Riboflavin in Neurological Diseases: A Narrative Review.
Clin Drug Investig. 2021 Jun;41(6):513-527. doi: 10.1007/s40261-021-01038-1. Epub 2021 Apr 22.
2
Neuropathy-causing TRPV4 mutations disrupt TRPV4-RhoA interactions and impair neurite extension.
Nat Commun. 2021 Mar 4;12(1):1444. doi: 10.1038/s41467-021-21699-y.
3
Natural history of Charcot-Marie-Tooth disease type 2A: a large international multicentre study.
Brain. 2020 Dec 1;143(12):3589-3602. doi: 10.1093/brain/awaa323.
4
Nutrition management guideline for very-long chain acyl-CoA dehydrogenase deficiency (VLCAD): An evidence- and consensus-based approach.
Mol Genet Metab. 2020 Sep-Oct;131(1-2):23-37. doi: 10.1016/j.ymgme.2020.10.001. Epub 2020 Oct 6.
5
Burst mitofusin activation reverses neuromuscular dysfunction in murine CMT2A.
Elife. 2020 Oct 19;9:e61119. doi: 10.7554/eLife.61119.
6
Disease mechanism, biomarker and therapeutics for spinal and bulbar muscular atrophy (SBMA).
J Neurol Neurosurg Psychiatry. 2020 Oct;91(10):1085-1091. doi: 10.1136/jnnp-2020-322949.
7
Animal Models of CMT2A: State-of-art and Therapeutic Implications.
Mol Neurobiol. 2020 Dec;57(12):5121-5129. doi: 10.1007/s12035-020-02081-3. Epub 2020 Aug 27.
8
Mitofusin 2 Dysfunction and Disease in Mice and Men.
Front Physiol. 2020 Jul 9;11:782. doi: 10.3389/fphys.2020.00782. eCollection 2020.
9
Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria.
N Engl J Med. 2020 Jun 11;382(24):2289-2301. doi: 10.1056/NEJMoa1913147.
10
Discovery of 6-Phenylhexanamide Derivatives as Potent Stereoselective Mitofusin Activators for the Treatment of Mitochondrial Diseases.
J Med Chem. 2020 Jul 9;63(13):7033-7051. doi: 10.1021/acs.jmedchem.0c00366. Epub 2020 Jun 18.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验